The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Flotetuzumab for primary induction failure & early relapse AML
John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, gives an update on the first-in-human Phase II study (NCT02152956) of flotetuzumab, an investigational CD123, CD3 bispecific antibody, currently in clinical development for patients exhibiting primary induction failure (PIF) and early relapse (ER) acute myeloid leukemia (AML). Cytokine release syndrome was the most frequently reported treatment-related adverse effect. In this study, flotetuzumab demonstrated encouraging activity in patients with PIF/ER AML, a population with poor prognosis and high unmet medical need. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
